Sun Pharma's Sonidegib Shows Promise Across Multiple Cancer Indications Beyond Basal Cell Carcinoma
Key Insights
Sonidegib phosphate (Odomzo), currently approved for locally advanced basal cell carcinoma (search), is being investigated for multiple additional cancer indications including gastroesophageal junction adenocarcinoma and medulloblastoma (search).
The oral anticancer agent, developed by Sun Pharma Advanced Research (search) (SPARC), has demonstrated potential in treating various solid tumors and hematologic malignancies, expanding its therapeutic scope.
The drug's development program spans across multiple challenging cancers, including glioblastoma (search), breast cancer, and chronic myelocytic leukemia (search), highlighting its potential as a versatile oncology treatment.
Sun Pharma Advanced Research (search) Company (SPARC) is advancing the development of sonidegib phosphate (Odomzo), an oral anticancer agent, beyond its current approved indication in basal cell carcinoma (search) (BCC). The drug's expanding clinical program demonstrates its potential to address multiple areas of unmet need in oncology.
Current Approval and Clinical Applications
Sonidegib phosphate, formulated as hard gelatin capsules for oral administration, is currently approved for adult patients with locally advanced BCC who have experienced disease recurrence following surgery or radiation therapy, or for those who are not candidates for these traditional treatments.
Expanding Therapeutic Horizons
The drug's development portfolio has expanded significantly, with active investigations in several high-priority indications. Current development focuses include:
- Adenocarcinoma of the gastroesophageal junction
- Newly diagnosed medulloblastoma
- Various hematologic malignancies
Comprehensive Development Program
SPARC's ambitious clinical program for sonidegib has explored its potential in numerous challenging cancers, including:
- Acute lymphocytic and myelocytic leukemia
- Platinum-resistant ovarian, fallopian tube, and peritoneal carcinomas
- Advanced hepatocellular carcinoma
- Recurrent glioblastoma multiforme
- Triple-negative breast cancer (ER-negative and HER2-negative)
- Castration-resistant prostate cancer
Novel Applications Beyond Oncology
Notably, the development program has also investigated sonidegib's potential in non-oncological conditions, including:
- Steroid-refractory chronic graft versus host disease (GVHD) following allogeneic HSCT
- Child-Pugh A cirrhosis
- Various forms of myelofibrosis
Corporate Leadership and Research Focus
SPARC, operating as a subsidiary of Shanghvi Finance (search) Pvt Ltd, maintains a comprehensive research and development approach. The company's therapeutic focus extends beyond oncology to include:
- Neurodegeneration
- Ophthalmology
- Dermatology
- Abuse-deterrent formulations
The ongoing development of sonidegib phosphate represents a significant component of SPARC's strategic focus on addressing unmet medical needs through innovative drug development.